The criteria for stopping Donanemab-azbt (Kisunla) therapy are primarily based on amyloid plaque reduction and safety monitoring, as outlined in clinical guidelines and prescribing information:Primary....
Copyright © 2025, PenDigest.com. All rights reserved
Published with
Typeflo